MPM Bioimpact LLC
In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 14, 2025), MPM Bioimpact LLC reported 47 stock positions worth $704.4 million. Its top holding was Cullinan Therapeutics (CGEM) at 13.2% of the portfolio, followed by Crinetics Pharmaceuticals (CRNX, 4.5%) and Edgewise Therapeutics (EWTX, 4.1%). Compared with Q3 2024, it opened 11 new positions, sold out of 7, added to 21 and reduced 11. The biggest buy was a new position in Zai Lab Ltd.-ADR (ZLAB) and the biggest sale Insmed (INSM, shares −37%).
- Most Recent 13F
- Q2 2026
- Location
- BOSTON, MA
- CIK
- 0001687078
- Portfolio Value
- $704.4M (Q4 2024)
- SEC Filing
- 0000950123-25-002794 ↗ filed Feb 14, 2025
Holdings Value
Holdings 47 stocks · $704.4M
| CGEM Cullinan Therapeutics Inc. | 13.23% | 7,648,268 | $93.2M | No change |
| CRNX Crinetics Pharmaceuticals Inc. | 4.48% | 617,035 | $31.5M | Add +17.3% |
| EWTX Edgewise Therapeutics Inc. | 4.09% | 1,079,316 | $28.8M | Add +17.7% |
| INSM Insmed Inc. | 3.82% | 389,611 | $26.9M | Reduce -36.7% |
| NTRA Natera Inc. | 3.61% | 160,626 | $25.4M | Reduce -9.3% |
| MIRM Mirum Pharmaceuticals Inc. | 3.46% | 589,579 | $24.4M | Add +19.7% |
| IRON Disc Medicine Inc. | 3.12% | 346,401 | $22.0M | Add +11.1% |
| LNTH Lantheus Holdings Inc. | 3.00% | 236,213 | $21.1M | Add +57.3% |
| ZLAB Zai Lab Ltd.-ADR | 2.97% | 800,000 | $21.0M | New |
| RNAM Avidity Biosciences Inc. | 2.90% | 702,981 | $20.4M | Add +2.0% |
| IOVA Iovance Biotherapeutics Inc. | 2.81% | 2,673,905 | $19.8M | Add +11.1% |
| PTCT PTC Therapeutics Inc. | 2.79% | 434,767 | $19.6M | Add +384.6% |
| WVE Wave Life Sciences Ltd. | 2.62% | 1,489,237 | $18.4M | Add +138.5% |
| SRRK Scholar Rock Holding Corp. | 2.55% | 416,144 | $18.0M | New |
| MLTX Moonlake Immunotherapeutics | 2.42% | 315,230 | $17.1M | Reduce -9.7% |
| OLMA Olema Pharmaceuticals Inc. | 2.41% | 2,912,550 | $17.0M | Add +8.7% |
| RARE Ultragenyx Pharmaceutical Inc. | 2.34% | 391,018 | $16.5M | Add +18.6% |
| CNTX Context Therapeutics Inc. | 2.19% | 14,705,882 | $15.4M | New |
| GH Guardant Health Inc. | 1.96% | 452,739 | $13.8M | Reduce -9.3% |
| RVMD Revolution Medicines Inc. | 1.95% | 313,817 | $13.7M | Add +7.7% |
| ITOS Iteos Therapeutics Inc. | 1.90% | 1,745,943 | $13.4M | No change |
| RNAC Cartesian Therapeutics Inc. | 1.83% | 721,139 | $12.9M | Add +14.6% |
| RCKT Rocket Pharmaceuticals Inc. | 1.82% | 1,020,559 | $12.8M | Reduce -4.3% |
| AKRO Akero Therapeutics Inc. | 1.82% | 460,617 | $12.8M | Add +17.3% |
| TRVI Trevi Therapeutics Inc. | 1.81% | 3,094,896 | $12.8M | Add +101.2% |
| TWST Twist Bioscience Corp. | 1.76% | 267,497 | $12.4M | Reduce -9.3% |
| CMPX Compass Therapeutics Inc. | 1.76% | 8,567,896 | $12.4M | Add +51.9% |
| JANX Janux Therapeutics Inc. | 1.75% | 230,000 | $12.3M | Add +34.4% |
| REPL Replimune Group Inc. | 1.63% | 950,000 | $11.5M | New |
| NUVB Nuvation Bio Inc. | 1.57% | 4,164,178 | $11.1M | New |
| VERA Vera Therapeutics Inc. | 1.55% | 257,788 | $10.9M | New |
| IDYA Ideaya Biosciences Inc. | 1.51% | 414,035 | $10.6M | New |
| RLAY Relay Therapeutics Inc. | 1.33% | 2,268,825 | $9.3M | Add +11.6% |
| UTHR United Therapeutics Corp. | 1.15% | 23,000 | $8.1M | New |
| ARCT Arcturus Therapeutics Holdin | 1.11% | 459,943 | $7.8M | Add +109.5% |
| XENE Xenon Pharmaceuticals Inc. | 1.10% | 197,212 | $7.7M | Add +18.9% |
| STOK Stoke Therapeutics Inc. | 1.07% | 685,826 | $7.6M | Add +43.0% |
| AQST Aquestive Therapeutics Inc. | 0.81% | 1,611,833 | $5.7M | Reduce -10.3% |
| AXSM Axsome Therapeutics Inc. | 0.60% | 50,000 | $4.2M | New |
| STRO Sutro Biopharma Inc. Com SHS | 0.56% | 2,160,062 | $4.0M | Reduce -23.7% |
| HOWL Werewolf Therapeutics Inc. | 0.50% | 2,388,011 | $3.5M | No change |
| DSGN Design Therapeutics Inc. | 0.49% | 559,547 | $3.5M | New |
| ZNTL Zentalis Pharmaceuticals Inc. | 0.48% | 1,106,851 | $3.4M | Reduce -24.5% |
| VERU Veru Inc. | 0.40% | 4,285,365 | $2.8M | New |
| ADAPY Adaptimmune Therapeutics-ADR | 0.39% | 5,095,912 | $2.7M | No change |
| ALXO Alx Oncology Holdings Inc. | 0.33% | 1,391,434 | $2.3M | Reduce -42.3% |
| RPTX Repare Therapeutics Inc. | 0.23% | 1,231,154 | $1.6M | Reduce -24.9% |
Portfolio Sells Q3 2024 → Q4 2024
| INSM Insmed Inc. | Reduce -36.7% | 3.82% | −2.92 |
| MDGL Madrigal Pharmaceuticals Inc. | Sold out | 0.00% | −2.30 |
| KALV Kalvista Pharmaceuticals Inc. | Sold out | 0.00% | −1.56 |
| VKTX Viking Therapeutics Inc. | Sold out | 0.00% | −1.15 |
| RCKT Rocket Pharmaceuticals Inc. | Reduce -4.3% | 1.82% | −1.13 |
| STRO Sutro Biopharma Inc. Com SHS | Reduce -23.7% | 0.56% | −0.91 |
| NTLA Intellia Therapeutics Inc. | Sold out | 0.00% | −0.82 |
| RPTX Repare Therapeutics Inc. | Reduce -24.9% | 0.23% | −0.62 |
| AQST Aquestive Therapeutics Inc. | Reduce -10.3% | 0.81% | −0.53 |
| ETNB 89BIO Inc. | Sold out | 0.00% | −0.37 |
| ZNTL Zentalis Pharmaceuticals Inc. | Reduce -24.5% | 0.48% | −0.33 |
| ALXO Alx Oncology Holdings Inc. | Reduce -42.3% | 0.33% | −0.33 |
| TWST Twist Bioscience Corp. | Reduce -9.3% | 1.76% | −0.23 |
| MLTX Moonlake Immunotherapeutics | Reduce -9.7% | 2.42% | −0.22 |
| RGNX Regenxbio Inc. | Sold out | 0.00% | −0.08 |
| SLDB Solid Biosciences Inc. | Sold out | 0.00% | −0.01 |
| NTRA Natera Inc. | Reduce -9.3% | 3.61% | +0.24 |
| GH Guardant Health Inc. | Reduce -9.3% | 1.96% | +0.25 |
Portfolio Buys Q3 2024 → Q4 2024
| ZLAB Zai Lab Ltd.-ADR | New | 2.97% | +2.97 |
| SRRK Scholar Rock Holding Corp. | New | 2.55% | +2.55 |
| PTCT PTC Therapeutics Inc. | Add +384.6% | 2.79% | +2.29 |
| CNTX Context Therapeutics Inc. | New | 2.19% | +2.19 |
| WVE Wave Life Sciences Ltd. | Add +138.5% | 2.62% | +1.85 |
| REPL Replimune Group Inc. | New | 1.63% | +1.63 |
| NUVB Nuvation Bio Inc. | New | 1.57% | +1.57 |
| VERA Vera Therapeutics Inc. | New | 1.55% | +1.55 |
| IDYA Ideaya Biosciences Inc. | New | 1.51% | +1.51 |
| UTHR United Therapeutics Corp. | New | 1.15% | +1.15 |
| TRVI Trevi Therapeutics Inc. | Add +101.2% | 1.81% | +1.04 |
| IRON Disc Medicine Inc. | Add +11.1% | 3.12% | +0.82 |
| AXSM Axsome Therapeutics Inc. | New | 0.60% | +0.60 |
| JANX Janux Therapeutics Inc. | Add +34.4% | 1.75% | +0.58 |
| MIRM Mirum Pharmaceuticals Inc. | Add +19.7% | 3.46% | +0.58 |
| LNTH Lantheus Holdings Inc. | Add +57.3% | 3.00% | +0.53 |
| DSGN Design Therapeutics Inc. | New | 0.49% | +0.49 |
| CRNX Crinetics Pharmaceuticals Inc. | Add +17.3% | 4.48% | +0.45 |
| EWTX Edgewise Therapeutics Inc. | Add +17.7% | 4.09% | +0.42 |
| VERU Veru Inc. | New | 0.40% | +0.40 |
| ARCT Arcturus Therapeutics Holdin | Add +109.5% | 1.11% | +0.34 |
| RNAC Cartesian Therapeutics Inc. | Add +14.6% | 1.83% | +0.31 |
| CMPX Compass Therapeutics Inc. | Add +51.9% | 1.76% | +0.21 |
| STOK Stoke Therapeutics Inc. | Add +43.0% | 1.07% | +0.19 |
| AKRO Akero Therapeutics Inc. | Add +17.3% | 1.82% | +0.13 |
| XENE Xenon Pharmaceuticals Inc. | Add +18.9% | 1.10% | +0.12 |
| RVMD Revolution Medicines Inc. | Add +7.7% | 1.95% | −0.03 |
| RARE Ultragenyx Pharmaceutical Inc. | Add +18.6% | 2.34% | −0.41 |
| IOVA Iovance Biotherapeutics Inc. | Add +11.1% | 2.81% | −0.58 |
| RLAY Relay Therapeutics Inc. | Add +11.6% | 1.33% | −0.83 |
| RNAM Avidity Biosciences Inc. | Add +2.0% | 2.90% | −1.85 |
| OLMA Olema Pharmaceuticals Inc. | Add +8.7% | 2.41% | −2.39 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 37 | $1.6B | CGEM, AKTS, LQDA, RVMD, CORT |
| Q1 2026 | 41 | $1.3B | DBVT, CGEM, AKTS, LQDA, ALMS |
| Q4 2025 | 38 | $874.0M | CGEM, MDGL, LQDA, TRVI, EWTX |
| Q3 2025 | 40 | $610.9M | MDGL, CGEM, RNAM, TRVI, EWTX |
| Q2 2025 | 44 | $577.2M | CGEM, MDGL, ZLAB, GH, SPRY |
| Q1 2025 | 43 | $581.7M | CGEM, MDGL, ZLAB, EWTX, LNTH |
| Q4 2024 | 47 | $704.4M | CGEM, CRNX, EWTX, INSM, NTRA |
| Q3 2024 | 43 | $666.6M | CGEM, INSM, OLMA, RNAM, CRNX |
| Q2 2024 | 44 | $643.5M | CGEM, INSM, OLMA, ITOS, CRNX |
| Q1 2024 | 38 | $622.0M | CGEM, GERN, IOVA, ZNTL, ITOS |